Solicitation
Epinephrine Injector
Department of Defense · Defense Logistics Agency
AI summaryThe Defense Logistics Agency (DLA Troop Support) wants one national supplier of epinephrine 0.3 MG/0.3 ML auto-injectors in 2-count boxes for the Department of Defense, Veterans Affairs, Indian Health Service and Bureau of Prisons. It is an unrestricted, fully competitive firm-fixed-price (FFP: one set price per unit) requirements contract (the Government buys what it needs from the one awardee; quantities are estimates) with one base year plus four one-year options. The estimated quantity is 473,905 BX (boxes) per year. SAM.gov gives the response due date as November 16, 2026, 3:00 PM Eastern, but the solicitation's bid-board instructions say November 2, 2026, 3:00 PM ET. More in the summary
AI summary Beta
This summary may miss requirements: 1 of 3 attachments weren't read (Amendment001.pdf). Check the attachments on SAM.gov.
The Defense Logistics Agency (DLA Troop Support) wants one national supplier of epinephrine 0.3 MG/0.3 ML auto-injectors in 2-count boxes for the Department of Defense, Veterans Affairs, Indian Health Service and Bureau of Prisons. It is an unrestricted, fully competitive firm-fixed-price (FFP: one set price per unit) requirements contract (the Government buys what it needs from the one awardee; quantities are estimates) with one base year plus four one-year options. The estimated quantity is 473,905 BX (boxes) per year. SAM.gov gives the response due date as November 16, 2026, 3:00 PM Eastern, but the solicitation's bid-board instructions say November 2, 2026, 3:00 PM ET.
Who can bid
- Open to all businesses: the buy is unrestricted, with no set-aside for small business programs
- Register for the DLA Internet Bid Board System (DIBBS) before sending an offer
- Large businesses need a subcontracting plan with the offer (approved before award for contracts expected to exceed $900,000)
How to submit: Upload the offer in the DLA Internet Bid Board System (DIBBS) at dibbs.bsm.dla.mil; email, mail and hand delivery are not authorized. What to include is under Full summary below. Check the solicitation's instructions on SAM.gov.
Things to watch (6)
From the version posted Oct 14, 2026.
- Serious: Must sign agreements with each prime vendor. The winner must reach a business-to-business agreement with every DLA and VA prime vendor; sales, payment terms and delivery run through those agreements, which a small business may find hard to negotiate.
- Serious: Large national volume and fast delivery. The estimate is 473,905 boxes per year, orders must be ready to fill 45 calendar days after award, and each complete order is due within 15 calendar days of receipt.
- Worth checking: Paid by prime vendors, not the Government. Payments come from the prime vendors, who adjust prices by distribution fees; those fees are currently negative, so the Government may pay less than the contract unit price.
Show all 6Show fewer
- Worth checking: Reverse auction may be used. After offers are evaluated the Government may run a reverse auction (bidders see the lowest price and lower their own); firms outside the competitive range are told before it starts.
- Worth checking: Quantities are estimates only. The 473,905 boxes per year are estimates; the Government does not promise to buy them and no price adjustment is owed if orders come in lower.
- Worth checking: Offers only through DIBBS. A DIBBS account is needed, and an upload problem is not accepted as a reason for a late offer.
Read from the notice and 2 attachments. 1 of 3 not read. Show which files.
- Ephinephrine Injector Solicitation.pdf (read)
- Ephinephrine Injector Solicitation_updated9.30.26.docx (read)
- Amendment001.pdf: not summarized: open it on SAM.gov
Full summary
What they want
- Supply epinephrine 0.3 MG/0.3 ML injection, auto-injector 2S, in 2-count boxes (unit of issue BX); the offer must give the product's National Drug Code (NDC: the drug's ID number)
- Estimated quantity 473,905 BX per year for the base year and each option year: Department of Defense 114,780, Veterans Affairs 336,610, Indian Health Service 22,515, Bureau of Prisons 0 (estimates only)
- Be ready to fill orders 45 calendar days after award, with enough stock to reach the prime vendors' distribution centers within 15 days of that date
- Deliver each complete order to the prime vendors (the DLA and VA pharmaceutical distributors) within 15 calendar days after receipt of order
- Sign a business-to-business agreement with each DLA and VA prime vendor covering payment terms and delivery, and tell the contracting officer within 15 days of receiving the award if any cannot be reached
- Invoice the prime vendors under those agreements, not the Government; contract prices take effect no more than 60 calendar days after award
- Fill initial orders of up to 30% of each agency's estimated annual quantity once the contract is in effect
- Meet the solicitation's rules on backorders, product registration, labeling, recalls, and a cost recovery fee with quarterly sales reports (listed in the table of contents; details attached but not read)
- Contract type
- Firm-fixed-price requirements contract (national contract, orders placed through the DLA and VA prime vendors)
- Period of performance
- 1 base year + 4 one-year options, 5 years at most
- Estimated value
- Not stated
- Contract vehicle
- National contract for the DLA and VA pharmaceutical prime vendor programs
- Offers due
- November 16, 2026, 3:00 PM Eastern
- How to submit
- Upload the offer in the DLA Internet Bid Board System (DIBBS) at dibbs.bsm.dla.mil; email, mail and hand delivery are not authorized
What to include when you submit
- Register in DIBBS before sending any offer, then upload the signed Standard Form 1449 (SF 1449: the form you sign as your offer) and all other documents before pressing submit
- Enter your Unique Entity Identifier and Commercial and Government Entity (CAGE) code in Block 17a, and your National Drug Code on item 0001
- Price each period (base year and four option years) on line item 0001, estimated quantity 473,905 BX each
- Give pricing information the solicitation asks for under its pricing-data provision: 2026 and 2025 commercial list prices, 2026 and 2025 Federal Supply Schedule prices, and 2026 and 2025 Federal Ceiling Prices, all without Federal Excise Tax
- Pick one way to receive paperless orders: electronic data interchange through an approved network, or email award notices with web links (requires DIBBS registration)
- Large businesses must send a subcontracting plan with their offer
After award, you must have
- Reach business-to-business agreements with each DLA and VA prime vendor (performance requirement after award; offerors may approach the prime vendors before sending an offer) From Ephinephrine Injector Solicitation_updated9.30.26.docx:
…the awarded contractor under this solicitation must reach a business-to-business agreement with each of the DLA and VA PPV contractors…
Current contractor
No incumbent is named in the text that was read.
Not in the notice text
- Large parts of the solicitation were attached but not read (about the middle half of both the PDF and the Word version), including the instructions to offerors, evaluation factors, backorder, product registration, labeling, drug application, manufacturing facility and recall requirements; check the solicitation on DIBBS or SAM.gov. Amendment001.pdf is also attached but not read.
- How offers will be evaluated and what must be in each volume of the proposal
- Which closing date applies: November 16, 2026 (SAM.gov) or November 2, 2026 (solicitation text)
- Place of performance is blank in SAM.gov; delivery is to prime vendor distribution centers whose locations the Statement of Work leaves to the awardee and the prime vendors
- The cost recovery fee amount and the quarterly sales report format
- Whether FDA approval, therapeutic equivalence or other drug-specific qualifications are required of bidders
Eligibility and how to respond
- No set-aside: any business, large or small, can bid unless the notice says otherwise.
- How to submit, from the AI summary: Upload the offer in the DLA Internet Bid Board System (DIBBS) at dibbs.bsm.dla.mil; email, mail and hand delivery are not authorized. Check it in the notice before you send anything.
Notice details
- Posted
- Oct 14, 2026
- Notice type
- Solicitation
- Office
- DLA Troop Support, Philadelphia, PA
- Product/service code
- 6505 · Drugs and Biologicals
- Business type
- Medical & healthcare (FedReady's grouping, from NAICS 325412)
- Versions
2 versions have been posted, newest first.
- Oct 14, 2026 · Amendment 0001 (this version)Due Nov 16, 2026 (changed)
- Oct 1, 2026 · SolicitationDue Nov 2, 2026
- Related notices
Other notices that name this solicitation, or that this one names.
- Alendronate Sodium Tablets · SPE2D2-26-D-0009Posted earlier Mar 19, 2026
- Fluconazole Tablets - SPE2D2-26-D-0003 · SPE2D2-26-D-0003Posted earlier Nov 3, 2025
- Attachments
Past awards and competition
Who has won work like this before, the likely incumbent, and what similar contracts paid, from USAspending.gov.
Before you respond
- How to respond to a solicitation (8 steps)
- How to read a government solicitation
- How to price a government contract
Terms on this notice: Solicitation
Full notice text from SAM.gov
Similar open opportunities
- Sacubitril/Valsartan Tablets (VA-27-00014055)This is a presolicitation: the Department of Veterans Affairs (VA) Enterprise Procurement Office plans to issue a request for proposals (RFP) for sacubitril-valsartan tablets on…
- Methylphenidate ERDLA Troop Support (Defense Logistics Agency) wants one national supplier of methylphenidate extended-release tablets in four strengths, in 100-count bottles.
- FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052Sources sought (market research only, not a solicitation): the Veterans Affairs Network Contract Office 10 wants to find firms that can supply unit-dose low energy…
- Lidocaine 5% Patches-Request for InformationThe Department of Veterans Affairs (VA) National CMOP Office is doing market research for L0515: Lidocaine 5% Patches, box of 30.
- TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform